echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Cell Death Differ: AQP1 may be used as an indicator for predicting the sensitivity of cycloviral drugs in breast cancer patients.

    Cell Death Differ: AQP1 may be used as an indicator for predicting the sensitivity of cycloviral drugs in breast cancer patients.

    • Last Update: 2020-09-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Breast cancer is the most common malignant tumor in women.
    is a conventional and widely used first-line chemotherapy drug for the treatment of breast cancer.
    , however, a ring-based treatment can only reduce breast cancer mortality by 20 to 30 per cent, and not all breast cancer patients benefit from it, and there are no suitable biomarkers to predict the effectiveness of chemotherapy.
    , a reliable marker is needed to predict a patient's sensitivity to cyclocystic drugs in order to better identify the most appropriate treatment strategy to improve patient survival.
    study, researchers revealed that the AQP1 protein could be a potential reaction predictor during chemotherapy for cyclocyclin drugs.
    researchers found that patients with high levels of AQP1 expression had better clinical outcomes than those with low levels of AQP1 expression in breast cancer patients treated with cyclocyclinic drugs.
    mechanism studies have shown that AQP1 and GSK3 beta (glycogenase kinase 3 beta) are competitively interacted with the 12repeat sequences of beta-catenin, inhibiting the degradation of beta-catenin, which leads to beta-catenin accumulation and nuclear transport in the cytoste.
    the nucleation of the beta-catenin can interact with TopoII alpha and enhance the activity of TopoII alpha, resulting in breast cancer cells being highly sensitive to cyclocyctic drugs.
    researchers also found that miR-320a-3p can reduce the chemotherapy sensitivity of cyclopenoids by inhibiting the expression of AQP1.
    the results of the study, which showed that AQP1 could serve as a predictive indicator in chemotherapy for cyclocyctic drugs, could help improve the prognostics of breast cancer patients who are better suited to chemotherapy with cyclocyclyctic drugs (high levels of AQP1 expression).
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.